- Previous Close
68.16 - Open
68.49 - Bid 69.47 x 400
- Ask 72.60 x 100
- Day's Range
67.77 - 69.58 - 52 Week Range
67.75 - 99.56 - Volume
1,325,615 - Avg. Volume
1,758,410 - Market Cap (intraday)
13.234B - Beta (5Y Monthly) 0.31
- PE Ratio (TTM)
52.66 - EPS (TTM)
1.32 - Earnings Date Oct 30, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
103.45
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
www.biomarin.comRecent News: BMRN
View MorePerformance Overview: BMRN
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BMRN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BMRN
View MoreValuation Measures
Market Cap
13.23B
Enterprise Value
13.11B
Trailing P/E
52.66
Forward P/E
17.01
PEG Ratio (5yr expected)
0.42
Price/Sales (ttm)
5.22
Price/Book (mrq)
2.50
Enterprise Value/Revenue
5.06
Enterprise Value/EBITDA
31.10
Financial Highlights
Profitability and Income Statement
Profit Margin
9.91%
Return on Assets (ttm)
2.23%
Return on Equity (ttm)
5.10%
Revenue (ttm)
2.59B
Net Income Avi to Common (ttm)
256.59M
Diluted EPS (ttm)
1.32
Balance Sheet and Cash Flow
Total Cash (mrq)
1.22B
Total Debt/Equity (mrq)
20.80%
Levered Free Cash Flow (ttm)
67.74M
Research Analysis: BMRN
View MoreCompany Insights: BMRN
BMRN does not have Company Insights
Research Reports: BMRN
View MoreRaising target price to $74.00
BIOMARIN PHARMACEUTICAL INC has an Investment Rating of HOLD; a target price of $74.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLowering target price to $74.00
BIOMARIN PHARMACEUTICAL INC has an Investment Rating of HOLD; a target price of $74.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetBioMarin: Potential Voxzogo Competition Lowers Our Valuation, but Shares Look Attractive
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
RatingPrice TargetBioMarin: Potential Voxzogo Competition Lowers Our Valuation, but Shares Look Attractive
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
RatingPrice Target